Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer. NICE technology appraisal guidance 1138
National Institute for Health and Care Excellence (NICE)
Record ID 32018015161
English
Details
Project Status:
Completed
URL for project:
https://www.nice.org.uk/guidance/ta1138
Year Published:
2026
URL for published report:
https://www.nice.org.uk/guidance/ta1138
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England
MeSH Terms
- Urinary Bladder Neoplasms
- Antineoplastic Combined Chemotherapy Protocols
- Gemcitabine
- Cisplatin
- Antineoplastic Agents, Immunological
- Antibodies, Monoclonal
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
3rd floor, 3 Piccadilly Place, Manchester, M1 3BN
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.